New nanoparticle chemo shows promise in early trial for tough cancers
NCT ID NCT04640480
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new drug called SNB-101 in 21 people with advanced solid tumors (like colorectal, breast, and lung cancers) that had stopped responding to standard treatments. SNB-101 is a nanoparticle version of SN-38, the active part of a common chemotherapy drug. The main goals were to check safety, find the right dose, and see how the body processes the drug. The study is now complete.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SNB-101 (nanoparticle form of SN-38, the active part of the chemotherapy drug irinotecan)
What this could lead to
If successful, this could lead to a better-tolerated version of a common chemotherapy for several advanced cancers.
What could go wrong
This is a very early, small Phase 1 trial focused on safety and dosing, not on proving the drug works. Side effects like low blood counts and liver issues are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHA Medical Center
Seongnam-si, Gyeonggi-do, 13496, South Korea
-
The Catholic University of Korea Seoul ST. Mary's Hospital
Seoul, Seoul, 06591, South Korea
-
The Severance Hospital of the Yonsei University
Seoul, Seoul, 03722, South Korea